FAQ: Lantern Pharma's RADR® Platform and Pediatric Brain Cancer Treatment Development

What is the main focus of Lantern Pharma’s recent development announcement?

Lantern Pharma is developing clinical trials using its AI platform and drug candidates to target rare pediatric brain cancers, specifically Atypical Teratoid Rhabdoid Tumor (ATRT), with its investigational therapy LP-184/STAR-001.

What is the RADR® platform and how does it support Lantern Pharma’s drug development?

RADR® is Lantern Pharma’s proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and 200+ advanced ML algorithms to accelerate oncology drug discovery and development, helping identify and optimize combination regimens.

When is Lantern Pharma planning to launch its clinical trial for pediatric brain cancer?

The company is planning to launch a clinical trial targeting rare pediatric brain cancer in Q1 2026.

What regulatory designations has Lantern Pharma received for its ATRT program?

The ATRT program has received both Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA.

What was the outcome of Lantern Pharma’s recent FDA meeting?

The company had a constructive Type C meeting with the FDA that provided positive feedback and critical guidance on trial design and regulatory pathway, reinforcing their approach.

How does LP-184/STAR-001 therapy work in treating pediatric brain cancers?

The therapy is designed to work synergistically with diuretic spironolactone and other potential combination regimens in treating childhood brain cancers, specifically targeting central nervous system (CNS) cancers.

What are the efficiency benefits of Lantern Pharma’s AI-driven approach to drug development?

On average, Lantern’s newly developed drug programs advance from initial AI insights to first-in-human clinical trials in 2-3 years at approximately $2.5 million per program.

What is the next regulatory step for Lantern Pharma’s pediatric cancer program?

The company is preparing to submit an investigational new drug (IND) amendment for its ATRT program.

Where can investors find more information and updates about Lantern Pharma?

The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.

What types of cancers does Lantern Pharma’s pipeline address?

Lantern Pharma’s growing pipeline of therapies spans multiple cancer indications, including both solid tumors and blood cancers, with a current focus on central nervous system cancers like ATRT.